Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 5/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | BCAT2 | O15382 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265344 | 0.86 | HPGD (1.00) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL263739 | 0.81 | BCAT2 (1.00) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL19119395 | 0.80 | BCAT2 (0.76) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL27273135 | 0.80 | BCAT2 (0.76) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL4529194 | 0.79 | KDM4E (0.64) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL23209156 | 0.78 | BCAT2 (0.72) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL14635195 | 0.78 | KDM4E (0.62) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL4927869 | 0.77 | KDM4E (0.78) | KDM4ELMNAGAAHPGDALDH1A1 | |
| SCHEMBL4524089 | 0.77 | MAPT (0.74) | KDM4ELMNAGAAHTTHPGD | |
| SCHEMBL23267317 | 0.77 | BCAT2 (0.70) | KDM4ELMNAGAAHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015136557-A9 | CANCER STEM CELL TARGETING COMPOUNDS | GODAVARI BIOREFINERIES LIMITED (IN) | 2022-05-27 | — | — | WO | disclosed |
| US-20180169100-A1 | Cancer Stem Cell Targeting Compounds | GODAVARI BIOREFINERIES LIMITED (IN) | 2018-06-21 | — | — | US | disclosed |
| US-20170022215-A1 | Compounds for Eradicating or Inhibiting Proliferation of Cancer Stem Cells | GODAVARI BIOREFINERIES LIMITED (IN) | 2017-01-26 | — | — | US | disclosed |
| EP-3116867-A2 | CANCER STEM CELL TARGETING COMPOUNDS | Godavari Biorefineries Ltd. (IN) | 2017-01-18 | — | — | EP | disclosed |
| EP-3116882-A2 | COMPOUNDS FOR ERADICATING OR INHIBITING PROLIFERATION OF CANCER STEM CELLS | Godavari Biorefineries Ltd. (IN) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015136557-A2 | CANCER STEM CELL TARGETING COMPOUNDS | GODAVARI BIOREFINERIES LIMITED (IN) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015136556-A2 | COMPOUNDS FOR ERADICATING OR INHIBITING PROLIFERATION OF CANCER STEM CELLS | GODAVARI BIOREFINERIES LIMITED (IN) | 2015-09-17 | — | — | WO | disclosed |
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | disclosed |
| US-7642257-B2 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642257-B2 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-7419978-B2 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419978-B2 | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080167304-A1 | PHENYL-ANILINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-10 | — | — | US | disclosed |
| US-20080167304-A1 | PHENYL-ANILINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1G, RYR1 | KDM4E 4160/4885LMNA 2366/4885GAA 3277/4885 |
| US-20180169100-A1 | Cancer Stem Cell Targeting Compounds | MCL1, MKI67, BAX | KDM4E 1934/4885LMNA 3132/4885GAA 554/4885 |
| US-20080167304-A1 | PHENYL-ANILINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | KDM4E 494/4885LMNA 1208/4885GAA 3050/4885 |
| US-20170022215-A1 | Compounds for Eradicating or Inhibiting Proliferation of Cancer Stem Cells | MCL1, MKI67, BCL2 | KDM4E 1681/4885LMNA 3311/4885GAA 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.